Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Bormioli Pharma Invests in Type I Glass Vial Production | Contract Pharma

What are you searching for?

Sign in
Breaking News

Bormioli Pharma Invests in Type I Glass Vial Production

Increases efficiency, reduces carbon footprint, and improves quality control standards and product finishing.

By: Contract Pharma

Contract Pharma Staff

Bormioli Pharma has completed the refurbishment of its glass furnace in San Vito al Tagliamento, where technological solutions and Industry 4.0 concepts have been implemented in order to increase production efficiency, reduce the carbon footprint, and improve quality control standards and product finishing.
 
This molded glass furnace refurbishment completes the revamping project of the entire plant initiated in 2019. The new equipment allows an increase in the glass melting power, thus improving the quality of the final product. Thanks to a proprietary this furnace ensures ideal glass distribution, as well as the production of both transparent and amber type I glass bottles, responding in a more effective way to the increased demand for glass vials used for complex drug formulations such as vaccines and several life-saving medicines.
 
The flexibility on the control of the energy consumption and the real-time monitoring emissions will also reduce the environmental impact of the plant anticipating the new EU sustainability protection policies.
 
“Thanks to these new investments, we have consistently increased our industrial capacity on glass pharma packaging production, whilst strengthening our capability to provide a complete packaging solution for injectable drugs,” commented Andrea Lodetti, CEO at Bormioli Pharma. “We are proud to be able to support more and better our partners in the pharma industry, helping to bring essential drugs and therapies where they’re needed the most, especially during these challenging times.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters